Bile acid receptor agonist reverses TGF-β1-mediated fibrogenesis in human induced pluripotent stem cells (iPSC)-derived kidney organoids

[1]  M. Bekheirnia,et al.  Disease modeling of ADAMTS9-related nephropathy using kidney organoids reveals its roles in tubular cells and podocytes , 2023, Frontiers in Medicine.

[2]  I. K. Yazdi,et al.  ATP/ADP biosensor organoids for drug nephrotoxicity assessment , 2023, Frontiers in Cell and Developmental Biology.

[3]  S. Tran,et al.  Microfluidic Organ-on-A-chip: A Guide to Biomaterial Choice and Fabrication , 2023, International journal of molecular sciences.

[4]  T. Rabelink,et al.  Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids , 2023, Frontiers in Immunology.

[5]  Y. Toh,et al.  The FDA modernisation act 2.0: bringing non-animal technologies to the regulatory table. , 2023, Drug discovery today.

[6]  Xiangyun Meng,et al.  New Drugs for Hepatic Fibrosis , 2022, Frontiers in Pharmacology.

[7]  S. Borwornpinyo,et al.  Establishment and Characterization of MUi027-A: A Novel Patient-Derived Cell Line of Polycystic Kidney Disease with PKD1 Mutation , 2022, Journal of personalized medicine.

[8]  Kin F. Chan,et al.  NUAK1 promotes organ fibrosis via YAP and TGF-β/SMAD signaling , 2022, Science Translational Medicine.

[9]  M. M.,et al.  Human iPSC-derived renal organoids engineered to report oxidative stress can predict drug-induced toxicity , 2022, iScience.

[10]  Victor G. Puelles,et al.  Decoding myofibroblast origins in human kidney fibrosis , 2020, Nature.

[11]  S. Calatayud,et al.  Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment? , 2020, Cells.

[12]  J. Dufour,et al.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. , 2019, Lancet.

[13]  M. Whitfield,et al.  Shared and distinct mechanisms of fibrosis , 2019, Nature Reviews Rheumatology.

[14]  D. Goldstein,et al.  Alpha-Synuclein Deposition Within Sympathetic Noradrenergic Neurons Is Associated With Myocardial Noradrenergic Deficiency in Neurogenic Orthostatic Hypotension , 2019, Hypertension.

[15]  P. Boor,et al.  Cellular and molecular mechanisms of kidney fibrosis. , 2019, Molecular aspects of medicine.

[16]  M. Finch-Edmondson,et al.  YAPping about and not forgetting TAZ , 2019, FEBS letters.

[17]  R. Nishinakamura,et al.  Organoids from Nephrotic Disease-Derived iPSCs Identify Impaired NEPHRIN Localization and Slit Diaphragm Formation in Kidney Podocytes , 2018, Stem cell reports.

[18]  H. Hagmann,et al.  Experimental Models to Study Podocyte Biology: Stock-Taking the Toolbox of Glomerular Research , 2018, Front. Pediatr..

[19]  A. Pini,et al.  Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model , 2018, Journal of Endocrinological Investigation.

[20]  Matthias Kretzler,et al.  High-Throughput Screening Enhances Kidney Organoid Differentiation from Human Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping. , 2018, Cell stem cell.

[21]  G. Karaca,et al.  Interleukin-1β Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis. , 2018, Journal of the American Society of Nephrology : JASN.

[22]  B. Ren,et al.  The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell , 2018, The Journal of Biological Chemistry.

[23]  A. Oshlack,et al.  Patient-iPSC-Derived Kidney Organoids Show Functional Validation of a Ciliopathic Renal Phenotype and Reveal Underlying Pathogenetic Mechanisms. , 2018, American journal of human genetics.

[24]  J. Gorodkin,et al.  TISSUES 2.0: an integrative web resource on mammalian tissue expression , 2018, Database J. Biol. Databases Curation.

[25]  Jiaqi Tang,et al.  Deregulation of Hippo–TAZ pathway during renal injury confers a fibrotic maladaptive phenotype , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  R. Nishinakamura,et al.  Higher-Order Kidney Organogenesis from Pluripotent Stem Cells. , 2017, Cell stem cell.

[27]  K. Guan,et al.  Regulation of the Hippo Pathway Transcription Factor TEAD. , 2017, Trends in biochemical sciences.

[28]  E. Gratton,et al.  FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. , 2017, Journal of the American Society of Nephrology : JASN.

[29]  Benjamin S. Freedman,et al.  Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease , 2017, Nature materials.

[30]  Benjamin S. Freedman,et al.  Gene‐Edited Human Kidney Organoids Reveal Mechanisms of Disease in Podocyte Development , 2017, Stem cells.

[31]  C. Harrison,et al.  Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis , 2017, Front. Pharmacol..

[32]  Yuhuan Luo,et al.  A dual agonist of farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice , 2017, The Journal of Biological Chemistry.

[33]  P. Boor,et al.  Treatment of Renal Fibrosis-Turning Challenges into Opportunities. , 2017, Advances in chronic kidney disease.

[34]  J. Bonventre,et al.  Generation of nephron progenitor cells and kidney organoids from human pluripotent stem cells , 2016, Nature Protocols.

[35]  F. He,et al.  Activation of FXR protects against renal fibrosis via suppressing Smad3 expression , 2016, Scientific Reports.

[36]  L. Becker,et al.  SCARB1 Gene Variants Are Associated With the Phenotype of Combined High High-Density Lipoprotein Cholesterol and High Lipoprotein (a). , 2016, Circulation. Cardiovascular genetics.

[37]  M. Takasato,et al.  Generation of kidney organoids from human pluripotent stem cells , 2016, Nature Protocols.

[38]  Zefeng Wang,et al.  A splicing isoform of TEAD4 attenuates the Hippo–YAP signalling to inhibit tumour proliferation , 2016, Nature Communications.

[39]  Xiao-ming Meng,et al.  TGF-β: the master regulator of fibrosis , 2016, Nature Reviews Nephrology.

[40]  V. D’Agati,et al.  G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes. , 2016, Journal of the American Society of Nephrology : JASN.

[41]  Robert G. Parton,et al.  Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis , 2016, Nature.

[42]  B. Hinz,et al.  YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis. , 2016, Journal of the American Society of Nephrology : JASN.

[43]  Jiaquan Xu,et al.  Deaths: Final Data for 2013. , 2016, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[44]  Jing Zhou,et al.  Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids , 2015, Nature Communications.

[45]  S. Lopes,et al.  Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis , 2015, Nature.

[46]  David W. Nauen,et al.  Synaptic dysregulation in a human iPS cell model of mental disorders , 2014, Nature.

[47]  J. Duffield.  Cellular and molecular mechanisms in kidney fibrosis. , 2014, The Journal of clinical investigation.

[48]  Xiang-Dong Fu,et al.  Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling , 2012, Cell.

[49]  Hidemi Ito,et al.  TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth , 2012, The Journal of experimental medicine.

[50]  M. Le Hir,et al.  Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? , 2011, The Journal of clinical investigation.

[51]  L. Adorini,et al.  Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist , 2010, Molecular Pharmacology.

[52]  M. Yaffe,et al.  TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal , 2008, Nature Cell Biology.

[53]  H. Ko,et al.  Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1 , 2007, Proceedings of the National Academy of Sciences.

[54]  T. Magnuson,et al.  Defects in Yolk Sac Vasculogenesis, Chorioallantoic Fusion, and Embryonic Axis Elongation in Mice with Targeted Disruption of Yap65 , 2006, Molecular and Cellular Biology.

[55]  Christophe Mulle,et al.  An automated method to quantify and visualize colocalized fluorescent signals , 2005, Journal of Neuroscience Methods.

[56]  L. Becker,et al.  Signal Transducer and Activator of Transcription 3α and Specificity Protein 1 Interact to Upregulate Intercellular Adhesion Molecule-1 in Ischemic–Reperfused Myocardium and Vascular Endothelium , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[57]  Masataka Harada,et al.  A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.

[58]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[59]  M. Levi,et al.  Bile acid receptors and the kidney , 2018, Current opinion in nephrology and hypertension.

[60]  K. Luo,et al.  Signaling Cross Talk between TGF-β/Smad and Other Signaling Pathways. , 2017, Cold Spring Harbor perspectives in biology.

[61]  Maria João Pires,et al.  Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. , 2017, In vivo.